Editors & Staff
Shachi Bhatt, Executive Editor, JEM
Shachi received her PhD in Anatomy and Cell Biology from University of Kansas Medical Center. She pursued her postdoctoral research in the lab of Paul Trainor at the Stowers Institute for Medical Research, where she studied the development of peripheral nervous and vascular systems, WNT/β-catenin signaling, and neural crest cell induction and differentiation. She has been a professional editor since 2017 when she joined Journal of Experimental Medicine as a scientific editor. Shachi joined Life Science Alliance as Executive Editor in August 2020, and was appointed Executive Editor of Journal of Experimental Medicine in May 2021.
Declares no conflict of interest.
Montserrat Cols, Senior Scientific Editor
Montserrat (Montse) received her PhD from Keele University in the UK. She then trained with Dr. Andrea Cerutti at Mount Sinai School of Medicine and more recently worked with Dr. Jayanta Chaudhuri at the Sloan Kettering Institute. Throughout her training and appointments, her particular focus has been on many aspects relating to B cell biology. Montse joined the Journal of Experimental Medicine as a Scientific Editor in 2020.
Declares no conflict of interest.
Xin (Cindy) Sun, Senior Scientific Editor
Xin (Cindy) received her PhD in Biochemistry and Molecular Biology from the Johns Hopkins University, studying the roles of RNA-binding proteins in DNA damage responses, NF-kB signaling and tumorigenesis. She then pursued her postdoctoral research in the lab of Robert Darnell at The Rockefeller University, where she studied RNA genomics in neurological disease and cancer. She joined the Journal of Experimental Medicine as a Scientific Editor in 2018. Cindy is in charge of JEM Special Collections.
Declares no conflict of interest.
Gaia Trincucci, Senior Scientific Editor
Gaia received her PhD in Cell Biology from the University of Basel, Switzerland, studying the role of Type III interferons in chronic hepatitis C. She pursued her postdoctoral work with Abraham Brass and Kate Fitzgerald at University of Massachusetts Medical School, focusing on uncovering novel host factors in viral replication. She joined the Journal of Experimental Medicine as a Scientific Editor in 2018. Gaia is in charge of JEM Viewpoints.
Declares no conflict of interest.
Lucie Van Emmenis, Scientific Editor
Lucie received her PhD from University College London, UK, under the supervision of Prof. Alison Lloyd studying the role of Schwann cells in peripheral nerve injuries. She then joined the lab of Dr. David S. Rickman at Weill Cornell Medicine where she studied the role of the microenvironment in promoting advanced prostate cancer. She joined the Journal of Experimental Medicine as a Scientific Editor in 2022.
Declares no conflict of interest.
Editorial Board Co-Chairs
Carl Nathan, Editorial Board Co-Chair
Carl Nathan is an R.A. Rees Pritchett Professor of Microbiology and Professor and Chairman of Microbiology, Immunology, and Medicine at Weill Cornell Medical College. After studying and working at Harvard College, Harvard Medical School, Massachusetts General Hospital, the National Cancer Institute, and Yale, Carl was board certified in internal medicine and oncology but decided on full-time research. For the first 10 years, his lab was in Zanvil Cohn’s group at The Rockefeller University. He then moved to the medical college at Cornell, where he has served as founding director of the Tri-Institutional MD-PhD Program, Senior Associate Dean for Research, Acting Dean, and Chairman of the Department of Microbiology and Immunology. Nathan began studying neutrophils in high school. His interests grew to include macrophages, tumor cells, inflammation, tuberculosis, reactive oxygen intermediates, reactive nitrogen intermediates, immunology, biochemistry, and chemical biology. Carl joined the editorial board of the Journal of Experimental Medicine as an Assistant Editor in 1981, and has been an Academic Editor since 1988.
Scientific advisory boards: Cancer Research Institute, Rita Allen Foundation, Lurie Prize jury for Foundation for the NIH, Bridge Medicines, Leap Therapeutics, Pfizer Centers for Therapeutic Innovation National Therapeutic Area Scientific Advisory Panel, Triterpenoid Therapeutics
Governing boards: Tres Cantos Open Lab Foundation, Tri-Institutional Therapeutics Discovery Institute.
Editorial boards: Journal of Experimental Medicine, Proceedings of the National Academy of Sciences, Science Translational Medicine.
Founder and Consultant: IpiNovyx Bio, Inc.
Consultant: Third Rock Ventures;
Patents: Compounds that target M. tuberculosis and P. falciparum and immunoproteasomes.
Funding sources: the Nathan lab receives grants from the National Institutes of Health and Bill & Melinda Gates Foundation. The Nathan lab has a collaborative research agreement with Celgene Global Health related to TB drug discovery.
Michel Nussenzweig, Editorial Board Co-Chair
Michel Nussenzweig is a Sherman Fairchild Professor, Senior Physician, and a Howard Hughes Investigator at The Rockefeller University. Michel earned a PhD from The Rockefeller University for his work with Ralph Steinman on dendritic cells and an MD from NYU Medical School. Following training in medicine and infectious diseases at the Massachusetts General Hospital, he worked with Dr. Philip Leder in the Department of Genetics at Harvard Medical School on antibody genes. His laboratory focuses on understanding B cell and dendritic cell physiology. Michel became an Academic Editor of the Journal of Experimental Medicine in 1995.
Scientific Advisory Board: CellDex Therapeutics, Frontier Biotechnology, the Austrian Academy of Sciences, and the Jackson Laboratory.
Editorial Boards: Journal of Experimental Medicine and Journal of Immunological Methods.
Patents: Rockefeller University owns patents for the 3BNC117 antibody being developed by Frontier Biotechnology. Michel Nussenzweig is an inventor on patents for antibodies to HIV-1 that have been licensed to Gilead by Rockefeller University. The Rockefeller University has applied for patents on SARS-2 antibodies on which Michel Nussenzweig is an inventor. The Rockefeller University has licensed the SARS-2 antibodies to Bristol Meyers Squibb.
Funding sources: the Nussenzweig laboratory receives research grants from the National Institutes of Health, The Bill and Melinda Gates Foundation, The Lyda Hill Foundation, The Wennett Cader Foundation, The Robertson Fund of the Rockefeller University. Dr. Nussenzweig is an HHMI investigator.
Yasmine Belkaid, Editor
Yasmine Belkaid obtained her PhD in 1996 from the Pasteur Institute in France exploring innate immune responses to parasitic infections. After a postdoctoral fellowship at the National Institute of Allergy and Infectious Diseases (NIAID) in the US, she joined the Children’s Hospital Research Foundation in Cincinnati as an assistant professor. In 2005, she joined NIAID and was appointed Senior Scientist in 2008. She is currently the chief of the Mucosal Immunology Section and Director of the NIAID Microbiome initiative. Her work explores mechanisms that regulate host immune responses to microbes at barrier sites and revealed key roles for the microbiota and dietary factors in the maintenance of tissue immunity and homeostasis. Yasmine joined JEM as Academic Editor in 2017.
Scientific Advisory Board: Keystone Symposia's Scientific Advisory Board, Kennedy Institute, Oxford, and Instituto de Medicina Molecular IMM, Lisbon
Funding Sources: The Belkaid laboratory Is funded by the National Institute of Health.
Jean-Laurent Casanova, Editor
Jean-Laurent Casanova is a Professor at The Rockefeller University, Howard Hughes Medical Institute Investigator, and Head of the St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch. He is also a Professor at the Necker Hospital for Sick Children, Paris Descartes University, where the Necker Branch of the Laboratory is located. Jean-Laurent received his PhD from the Pierre et Marie Curie Paris University in 1992 after being trained at the Pasteur Institute in Paris and the Ludwig Institute for Cancer Research in Lausanne. He received his MD in 1995 following medical studies and a residency in pediatrics in Paris. He then completed a clinical fellowship in the pediatric immunology−hematology unit of the Necker Hospital in Paris. In 1999 he was appointed a Professor of Pediatrics at Necker, where, with Laurent Abel, he cofounded and co-directed the Laboratory of Human Genetics of Infectious Diseases. He was recruited by the Rockefeller University in 2008. Work in his laboratory tests the hypothesis that severe infectious diseases may result from single-gene inborn errors of immunity. He has discovered genetic etiologies of various infectious diseases, including viral, bacterial, and fungal diseases. Jean-Laurent became an Academic Editor of the Journal of Experimental Medicine in 2006.
Scientific advisory boards/consulting: ADMA, Celgene, Elixiron Immunotherapeutics, KymeraTX.
Funding sources: the Casanova lab receives research grants from the Howard Hughes Medical Institute, Job Research Foundation, Lundbeck Foundation, National Institutes of Health, and Qatar National Research Fund.
Sara Cherry, Editor
Sara Cherry is a Professor in the Department of Pathology and Laboratory Medicine and the Department of Biochemistry and Biophysics, Scientific Director of the High-throughput Screening Core and Director of the Chemogenomic Discovery Program in the School of Medicine at the University of Pennsylvania. She obtained her BS with Dr. Peter Schultz at Berkeley synthesizing new biopolymers for drug scaffolds, and then her PhD with Dr. David Baltimore at MIT studying early B cell development. Next, she completed her postdoctoral fellowship with Dr. Norbert Perrimon where she developed high-throughput RNAi screening to study virus-host interactions. She started her laboratory at Penn in 2006 where she has applied cell-based screening approaches to discover mechanisms by which diverse viral pathogens hijack cellular machinery while evading innate immune defenses. Sara joined JEM as an Academic Editor in 2020.
Funding sources: the Cherry lab receives grants from the National Institutes of Health, Mark Foundation, and the Burroughs Wellcome Fund. The Cherry lab has a collaborative research agreement with Merck.
Susan Kaech, Editor
Susan Kaech, PhD, is currently Professor of Immunobiology in the Department of Immunobiology, Yale School of Medicine, New Haven, CT. Her laboratory aims to understand how memory T cells are generated during infection and vaccination and why, in some circumstances, an immunization fails to induce long-term T cell immunity. They are also learning how T cells are regulated in tumor microenvironments to better understand how their functions become suppressed as they infiltrate tumors in order to develop new methods of immunotherapy that enhance antitumor responses. Using several powerful model systems of infection or cancer in mice, they are elucidating mechanisms involved in the development of protective and long-lived memory T cells that form after acute infection or, conversely, of dysfunctional or “exhausted” T cells that form in tumors or during chronic viral infections. Their studies are aimed at identifying the signaling and metabolic pathways that regulate the differentiation of T cells in these different types of environments so that we can design new ways to optimize the formation of highly functional, protective memory T cells to fight infection and cancer. Susan joined JEM as Academic Editor in 2017.
Scientific advisory boards/consulting: Celsius Therapeutics, Vanderbilt Institute for Infection, Immunology and Inflammation, Bristol Myers Squibb
Susan Kaech is a Professor and Director of the NOMIS Center for Immunobiology and Microbial Pathogenesis at the Salk Institute.
Editorial Boards: Editorial Board member, Annual Reviews of Immunology, Academic Editor, Journal of Experimental Medicine, Editorial Board member, Immunity, Editorial Board member, Current Opinions in Immunology, Member of San Diego Center for Precision Immunology
Funding sources: the Kaech lab receives research grants or has sponsored research agreements from the National Institutes of Health, Cancer Research Institute, Tempest Therapeutics and the Salk Institute
Jonathan Kipnis, Editor
Dr. Jonathan (Jony) Kipnis is BJC Investigator, Alan A. and Edith L. Wolff Distinguished Professor of Pathology and Immunology, and Professor of Neurology, Neuroscience, and Neurosurgery at Washington University in St. Louis, School of Medicine. He is also an inaugural Director of Center for Brain immunology and Glia (BIG) at Washington University. Jony graduated from the Weizmann Institute of Science in Israel, where he was a Sir Charles Clore scholar and a recipient of distinguished prize for scientific achievements awarded by the Israeli Parliament, The Knesset. Kipnis lab focuses on the complex interactions between the immune system and the central nervous system (CNS). The goal is to elucidate the cellular and molecular mechanisms underlying these interactions in neurodegenerative, neurodevelopmental, and mental disorders as well as in physiology (including healthy aging). They showed that the brain function is dependent, in part, on the function and integrity of the immune system and that immune molecules (cytokines) can play neuromodulatory roles. The fascination with immunity and its role in neurophysiology is what brought the team to a breakthrough discovery of meningeal lymphatic vessels that drain the CNS into the peripheral lymph nodes and thus serve as a physical connection between the brain and the immune system. This finding challenged the prevailing dogma of CNS being an “immune privileged organ” and opened new avenues to mechanistically study the nature of neuroimmune interactions under physiological and pathological conditions. The implications of this work are broad and range from Autism to Alzheimer’s disease through neuroinflammatory conditions, such as Multiple Sclerosis. Dr. Kipnis is a recipient NIH Director’s Pioneer award for 2018 to explore in more depth neuro-immune interactions in healthy and diseased brain. Jonathan joined JEM as an academic editor in 2021.
Scientific advisory board/consulting: PureTech Health, Ionis
Editorial boards: Journal of Experimental Medicine, Trends in Immunology, Brain
Shareholder: PureTech Health
Funding sources: NIH, Cure Alzheimer’s Fund, Chen-Zuckerberg Initiative (CZI), BJC Health, PureTech Health
Lewis L. Lanier, Editor
Lewis L. Lanier is an American Cancer Society Research Professor, a Professor and Vice Chair of the Department of Microbiology and Immunology, and Professor of the Cancer Research Institute at the University of California, San Francisco. Lewis received his PhD in microbiology and immunology from the University of North Carolina at Chapel Hill. After postdoctoral studies, first at the Lineberger Cancer Center at UNC Chapel Hill and then as a Damon Runyon−Walter Winchell Cancer Research Fellow at the University of New Mexico, he joined the Research & Development Department at the Becton Dickinson Monoclonal Center in Mountain View, California, advancing to Associate Director of Research, and was a Becton Dickinson Research Fellow. In 1990, he joined the DNAX Research Institute of Molecular and Cellular Biology in Palo Alto, California, where he advanced to Director of Immunobiology. In 1999, Lewis joined the faculty of UCSF. His research group studies natural killer (NK) cells, which recognize and eliminate cells that have become transformed or infected by viruses. Lewis has been an Academic Editor of the Journal of Experimental Medicine since 2008.
Scientific Advisory Board: Five Prime Therapeutics, SBI Biotech Co. Ltd., Avidbiotics, Dragonfly, Ascend, Avipep, Atreca, Vivance, Alector, Valitor, Nkarta.
Editorial Boards: Journal of Experimental Medicine, Immunity, Tissue Antigens and Cancer Immunology Research.
Patents: U.S. Patents #6,140,076, #6,416,973, #6,479,638 B1, #6,953,843 B2, #7,319,140, #7,332,574, #7,659,093, #7,999,078, #7,998,481, #8,637,011, #9,211,328, #9,683,996.
Funding sources: NIAID, NCI, and the Parker Institute for Cancer Immunotherapy.
William A. (Bill) Muller, Editor Emeritus
William A. Muller is the Magerstadt Professor and Chairman of the Department of Pathology at Northwestern University Feinberg School of Medicine. He received his PhD degree from The Rockefeller University and an MD degree from Cornell University Medical College. He did residency/postdoctoral fellowship training at the Massachusetts General Hospital and Brigham and Women’s Hospital in Boston before returning to Rockefeller and Cornell to set up his own laboratory. Bill was recruited to Northwestern in 2007. His research interests focus on the cellular and molecular biology of the inflammatory response, particularly from the perspective of the vascular endothelial cell. His laboratory focuses on leukocyte−endothelial cell interactions and the role of the endothelial cell in regulating inflammation with the aim of designing more selective antiinflammatory therapies. Bill has played several major leadership roles in the American Society for Investigative Pathology and the North American Vascular Biology Organization. He has been on the editorial board of the Journal of Experimental Medicine since 1993 and became an Academic Editor in 1996.
Patents: Inventor on two patents currently held with Weill Cornell Medical School relating to the use of blocking CD99 and CD99L2, respectively as anti-inflammatory agents. These are currently not licensed. Two additional patents with Northwestern currently pending.
Royalties: Bill Muller receives royalties from Rockefeller University related to the licensing of the anti-CD31 monoclonal antibody hec7.
Funding sources: The Muller lab receives grants from the National Institutes of Health (NHLBI and NCI) and the Lefkofsky Family Foundation.
Anne O’Garra, Editor
Anne O'Garra is a Senior Group Leader of the Laboratory of Immunoregulation and Infection, and Associate Research Director, at The Francis Crick Institute, London. From 2001–2015, Anne was the Head of the Division of Immunoregulation at the National Institute for Medical Research (NIMR), Mill Hill, London, UK, now part of The Francis Crick Institute. Anne obtained her PhD at the NIMR working on bacterial adhesion and then moved fields and joined the Division of Immunology at NIMR as a Postdoctoral Fellow, where she studied the role of cytokines in B cell growth and differentiation. Anne moved to California in 1987, where she spent 15 years at the DNAX Research Institute. There, Anne's laboratory delineated mechanisms for the development of discrete subsets of CD4+ T cells and showed that this is determined by a number of factors, including cytokines, dose and form of antigens, and the antigen-presenting cells. A major focus of her work has been on the mechanisms for induction of the suppressive cytokine IL-10 and the function of this cytokine to regulate immune responses. Anne continues her research to interface immunology and infectious diseases, continuing to research the role and regulation of cytokines in immunoregulation, with a focus on the immune response in tuberculosis in mouse models and in human disease. Anne became an Academic Editor of the Journal of Experimental Medicine in 2004.
Scientific advisory boards: Keystone Conferences, USA; Kennedy Institute of Rheumatology, University of Oxford; MRC Weatherall Institute of Molecular Medicine, University of Oxford; National Research Foundation (NRF), Singapore; Jury Novartis Prizes for Immunology; Jury for the Sanofi – Institut Pasteur awards, France
Funding Sources: The O’Garra lab receives research grants from the The Francis Crick Institute which receives its core funding from Cancer Research UK (FC001126), the UK Medical Research Council (FC001126), and the Wellcome Trust (FC001126); Bioaster Microbiology Technology Institute, Lyon, France; Medical Diagnostic Discovery Department, bioMérieux SA, Marcy l’Etoile, France; and funded in part by Illumina Inc., San Diego, CA, USA; and O’Garra is soon to receive a Wellcome Investigator award.
Emmanuelle Passegué, Editor
Emmanuelle Passegué, PhD, is an Alumni Professor of Genetics and Development and Rehabilitation Medicine and the Director of the Columbia Stem Cell Initiative at Columbia University Medical Center. Before her recent move to Columbia University, Emmanuelle was Professor of Medicine in the Hematology/Oncology Division and the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the University of California, San Francisco. She received her PhD from the University Paris XI in France and performed postdoctoral trainings with Dr. Erwin Wagner at the Institute for Molecular Pathology in Austria and Dr. Irv Weissman at Stanford University. Emmanuelle’s research interests focus on the biology of blood-forming hematopoietic stem cells (HSCs) in normal and deregulated contexts such as stress, malignancies, and aging. She has received numerous Scholar Awards from the American Society of Hematology, the Rita Allen Foundation, the California Institute for Regenerative Medicine, and the Lymphoma and Leukemia Society. Emmanuelle joined JEM as Academic Editor in 2017.
Scientific advisory board/consulting: Damon Runyon Fellowship Award Committee (FAC), President Elected of the International Society of Experimental Hematology, active committee roles with ASH, ISSCR and ISEH.
Editorial boards: member of the Cell Stem Cell editorial board and scientific editor for BLOOD CANCER DISCOVERY.
Patents: Emmanuelle Passegué is an inventor on a patent licensed by Stanford University to the Jackson Laboratory for the commercialization of the MRP8-Cre-ires-GFP mice.
Funding sources: the Passegué lab receives research grants from the National Institute of Health, the Leukemia Lymphoma Society and the Glenn Foundation.
Alexander (Sasha) Rudensky, Editor
Alexander Rudensky is an HHMI Investigator and a member of the Department of Immunology at Memorial Sloan Kettering Cancer Center. Prior to his recent move to Sloan Kettering, he was Professor of Immunology at the University of Washington School of Medicine, Seattle, and Adjunct Professor at the A.N. Belozersky Institute of Physico-Chemical Biology, Moscow State University, Russia. Dr. Rudensky received his PhD degree from the Gabrichevsky Research Institute of Epidemiology and Microbiology, Moscow. After postdoctoral training at Yale University Medical School with Charles Janeway, he remained as an associate research scientist. Dr. Rudensky was a Searle Scholar and received a Pharmingen Investigator Award from the American Association of Immunologists.
Alexander Rudensky is studying the development of T lymphocytes, their function, and their role in the regulation of immune responses to infection and in the prevention of autoimmunity. His studies include investigation of the control of immune homeostasis by regulatory T cells and investigation of the molecular mechanisms instructing commitment of specialized T cell lineages.
Disclosure statement: (1) Co-founder and shareholder: Surface Oncology; (2) Co-founder: Vedanta Biosciences, Inc.
Scientific advisory boards/consulting: SAB: 1) Surface Oncology, Inc.; (2) Vedanta Biosciences, Inc.; (3) FLX Bio., Inc.; (4) BioInvent International AB; and (5) IFM Therapeutics, Inc. (6) Tsinghua University Institute for Immunology. Consultant: Omeros Corporation.
Patents: Dr. Rudensky is a co-inventor on patent applications, filed by MSK, related to anti-CCR8 antibodies for the treatment of cancer.
Funding sources: the Rudensky lab receives research grants from the National Institutes of Health, Parker Institute, Ludwig Cancer Research/Conrad Hilton Foundation. Dr. Rudensky is an Howard Hughes Medical Investigator and receives support for the overall research of the laboratory.
Arlene Sharpe, Editor
Arlene Sharpe, MD, PhD is the George Fabyan Professor of Comparative Pathology, Chair of the Department of Immunology at Harvard Medical School, and Co-Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital.
Dr. Sharpe earned her A.B. from Harvard University and her M.D. and Ph.D. degrees from Harvard Medical School. She completed residency training in Pathology at Brigham and Women’s Hospital and is board certified in Anatomic Pathology.
Dr. Sharpe is a leader in the field of T cell costimulation. Her laboratory has discovered and elucidated functions of T cell costimulatory pathways, including the immunoinhibitory functions of the CTLA-4 and PD-1 pathways, which are targets for cancer immunotherapy. Her laboratory currently investigates roles of T cell costimulatory pathways in cancer, autoimmunity, and infection. Dr. Sharpe has published over 300 papers and was listed by Thomas Reuters as one of the most Highly Cited Researchers (top 1%) in 2014-2018 and a 2016 Citation Laureate. She received the William B. Coley Award for Distinguished Research in Tumor immunology in 2014 and the Warren Alpert Foundation Prize in 2017 for her contributions to the discovery of PD-1 pathway. Dr. Sharpe is an elected member of the National Academy of Sciences and National Academy of Medicine and a Fellow of the American Association for Cancer Research.
Scientific advisory boards/consulting: SQZ Biotech, Surface Oncology, Elstar, Selecta, Elpiscience, Monopteros, SU2C
Patents: patents and/or pending royalties on the PD-1 pathway from Roche/Genentech and Novartis.
Funding sources: The Sharpe lab receives research grants from the National Institutes of Health, Novartis AG, Roche, UCB, Ipsen, Quark, Merck, Evergrande Center for Immunologic Diseases
Alan Sher, Editor Emeritus
Alan Sher is a Senior Investigator at the National Institute of Allergy and Infectious Diseases, NIH, where he heads the Laboratory of Parasitic Diseases. Alan obtained his PhD from the University of California, San Diego, for work done in the laboratory of Melvin Cohn, and he did postdoctoral training at the National Institute for Medical Research, Mill Hill, in the UK. He was a Research Associate and then Assistant Professor in the Department of Pathology at Harvard Medical School before joining the NIH. His group’s major interest has been in mechanisms of host resistance and immune regulation in parasitic and mycobacterial infections. Alan became an Academic Editor of the Journal of Experimental Medicine in 2007.
David Tuveson, Editor
David Tuveson is the Director of the Cold Spring Harbor Laboratory (CSHL) Cancer Center, the Roy J. Zuckerberg Professor of Cancer Research at CSHL, the head of the Lustgarten Foundation Pancreatic Cancer Research Laboratory at CSHL, and is also the Lustgarten Foundation’s Director of Research. Dr. Tuveson completed a bachelor's degree at MIT (Chemistry, 1987), the MD-PhD program at Johns Hopkins in 1994, an Internal Medicine residency at Brigham and Women's Hospital in 1997, and a Medical Oncology fellowship at Dana-Farber/Harvard in 2000. While at Dana-Farber, he co-developed Gleevec/Imatinib with George Demetri as a new treatment for patients with gastrointestinal stromal tumors (GIST). Dr Tuveson completed a postdoctoral fellowship with Tyler Jacks at MIT, where he developed several mouse cancer models and investigated GIST. He was appointed assistant Professor of Medicine at the University of Pennsylvania from 2002 to 2006, where his laboratory developed the ductal pancreatic cancer models. Dr. Tuveson moved in 2006 to the CRUK/Cambridge Research Institute at the University of Cambridge to establish a preclinical therapeutics laboratory and a pancreatic cancer clinical trials group. In Cambridge, his laboratory determined several mechanisms that contribute to drug resistance in pancreatic cancer, stimulating clinical trials in these areas. He was appointed Professor of Pancreatic Cancer Medicine at the University of Cambridge and Founder of the Pancreatic Cancer Centre. In 2012, Dr. Tuveson moved to Cold Spring Harbor Laboratory as Professor and director of the Cancer Therapeutics Program. His honors include the Rita Allen Foundation Scholar Award, the Waldenstrom Award (2014), the Hamdan Award (2016), and election to the American Society of Clinical Investigation (2016).
Disclosure statement: David Tuveson is a shareholder of Leap Therapeutics and Surface Oncology.
Scientific advisory boards/consulting: Leap Therapeutics, Surface Oncology, Bethyl Laboratory, ONO, Lustgarten Foundation, AACR, Stand up to Cancer, Georg-Speyer-Haus.
Patents: David Tuveson is an inventor on a patent licensed by Cold Spring Harbor Laboratory to BioNTech regarding CA19-9 antibodies for treatment and prevention of pancreatitis.
Funding sources: the Tuveson lab receives research grants from the National Institutes of Health, the Lustgarten Foundation, the V Foundation.
Jedd D. Wolchok, Editor
Jedd D. Wolchok, MD, PhD, FASCO is Chief of the Melanoma Service and holds The Lloyd J. Old Chair in Clinical Investigation at Memorial Sloan Kettering Cancer Center (MSK). He is also head of the Swim Across America - Ludwig Collaborative Laboratory; Associate Director of the Ludwig Center for Cancer Immunotherapy (LCCI); SU2C–ACS Lung Cancer Dream Team Co-leader and Director of the Parker Institute for Cancer Immunotherapy at MSK. Dr. Wolchok is a clinician-scientist exploring innovative immunotherapeutic strategies in laboratory models, and a principal investigator in numerous pivotal clinical trials. He specializes in the treatment of melanoma. The focus of his translational research laboratory is to investigate innovative means to modulate the immune response to cancer as well as to better understand the mechanistic basis for sensitivity and resistance to currently available immunotherapies.
Consultant for: Adaptive Biotech; Advaxis; Amgen; Apricity; Ascentage Pharma; Astellas; Beigene; Bristol Myers Squibb; Celgene; Chugai; Elucida; Eli Lilly; F Star; Genentech; Imvaq; Linneaus; MedImmune; Merck; Neon Therapuetics; Ono; Polaris Pharma; Polynoma; Psioxus; Puretech; Recepta; Trieza; Sellas Life Sciences; Surface Oncology.
Co-Founder and Shareholder: Tizona Pharmaceuticals; Trieza, Imvaq Therapeutics
Equity in: Adaptive Biotechnologies; Elucida; Beigene; Trieza; Linneaus. Kleo
Scientific Advisory Board member and Shareholder: Beigene
Patents: Xenogeneic DNA Vaccines; ALPHAVIRUS REPLICON PARTICLES EXPRESSING TRP2;Myeloid-derived suppressor cell (MDSC) assay; NEWCASTLE DISEASE VIRUSES FOR CANCER THERAPY; Genomic Signature to Identify Responders to Ipilimumab in Melanoma; Engineered Vaccinia Viruses for Cancer Immunotherapy; Anti-CD40 agonist mAb fused to Monophosphoryl Lipid A (MPL) for cancer therapy; CAR+ T cells targeting differentiation antigens as means to treat cancer; Anti-PD1 Antibody; Anti-CTLA4 antibodies; Anti-GITR antibodies and methods of use thereof.
Funding sources: the Wolchock lab receives funds from Bristol Myers Squibb; Genentech; Medimmune. The Wolchok lab receives grants from the NIH.
Consulting Biostatistical Editor
Xi Kathy Zhou, Consulting Biostatistical Editor
Xi Kathy Zhou is an Associate Professor of Biostatistics at Weill Cornell Medical College. She received her PhD degree in Statistics and Decision Sciences from Duke University. Her research interest is to develop and apply novel statistical methods to better design biological and clinical studies related to disease prevention, diagnosis and treatment and properly analyze data generated from such studies. Her methodological interest include Bayesian hierarchical models, model selection, model averaging, predictive modeling, and their applications to large complex datasets. She collaborates extensively with laboratory researchers and clinicians and has served as the Lead Biostatistician in clinical trials. Kathy became the Consulting Biostatistical Editor of the Journal of Experimental Medicine in 2016.
Sylvia Cuadrado, Senior Managing Editor
Sylvia has worked at The Rockefeller University Press since 2005. She loves TV and happy hour.
Elissa Hunter, Assistant Production Editor
Elissa Hunter joined Rockefeller University Press in July 2020 after more than a decade of working as a copy editor and proofreader, most recently at Marvel Entertainment and The Culture Trip. She has a BS in journalism from University of Florida, an MLIS from Pratt Institute, and no idea how she ended up with two science degrees.
Jennifer McGullam, Production Editor
Jenny joined Rockefeller University Press in 2018. She has been working in scientific and medical publishing for several years, most recently as a Production Editor at Springer Nature. Jenny studied English and linguistics at Dartmouth College and enjoys baking, reading, and exploring the outdoors.
Rochelle Ritacco, Preflight Editor
Rochelle is responsible for the preparation of figures for RUP publication—checking production quality, conforming style, and clarity of presentation. She is a skilled digital artist with expertise in many media applications. Rochelle began freelancing at RUP in 2007 and shortly thereafter joined the staff. Prior to RUP, she assisted the campus photographer at Monmouth University. Rochelle received her BA in communications from Seton Hill University and has completed two certificate programs, Digital Art (BCC) and Filmmaking (NYU). She is on the board of the Belmar Art Council. Rochelle lives along the dazzling north Jersey shore with her husband and daughter.
Laura Smith, Senior Preflight Editor
Laura began her career at The Rockefeller University in 1996 in the Office of Public Affairs. In 1997, she joined the RU Press as assistant to then director Michael Held. In 2002, under the guidance of Mike Rossner, Laura began image screening. She has since traveled abroad and throughout the United States training others in the detection of image manipulation. Laura lives in the Hudson Valley with her daughter and rescue kitty "Wiki".
Frederick W. Alt
Christine A. Biron
Robert L. Coffman
Myron I. Cybulsky
Richard A. Flavell
Ronald N. Germain
Margaret (Peggy) Goodell
Christopher A. Hunter
Vijay K. Kuchroo
Bart N. Lambrecht
Klaus F. Ley
Sean J. Morrison
John J. O’Shea
Gwendalyn J. Randolph
David L. Sacks
Matthew D. Scharff
Stephen P. Schoenberger
Charles N. Serhan
Ethan M. Shevach
Roy L. Silverstein
Steven L. Teitelbaum
Kevin J. Tracey
Raymond M. Welsh
E. John Wherry
Kristin A. Hogquist